Lv1
50 积分 2022-03-02 加入
TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial
9天前
已关闭
Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer
1个月前
已完结
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
4个月前
已完结
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
4个月前
已完结
Combined oral PI3Kδ inhibitor linperlisib and HDAC inhibitor chidamide in relapsed/refractory peripheral T-cell lymphoma: a multicenter phase 1 trial
5个月前
已完结
Insomnia: Personalized Diagnosis and Treatment Options
8个月前
已关闭
Insomnia
8个月前
已关闭
Newly identified adverse events for gemcitabine using the Food and Drug Administration Adverse Event Reporting System
10个月前
已完结
New exploration of signal detection of Regional Risks from the perspective of data mining: a pharmacovigilance analysis based on spontaneous reporting data in Zhenjiang, China
10个月前
已完结
皖公网安备34019202002308
